Home › Compare › HUMDF vs O

HUMDF vs O: Dividend Comparison 2026

HUMDF yields 484.14% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HUMDF wins by $47899.98M in total portfolio value
10 years
HUMDF
HUMDF
● Live price
484.14%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47900.01M
Annual income
$34,060,653,223.60
Full HUMDF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — HUMDF vs O

📍 HUMDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHUMDFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HUMDF + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
HUMDF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HUMDF
Annual income on $10K today (after 15% tax)
$41,152.26/yr
After 10yr DRIP, annual income (after tax)
$28,951,555,240.06/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, HUMDF beats the other by $28,951,550,902.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HUMDF + O for your $10,000?

HUMDF: 50%O: 50%
100% O50/50100% HUMDF
Portfolio after 10yr
$23950.02M
Annual income
$17,030,329,163.17/yr
Blended yield
71.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

HUMDF
No analyst data
Altman Z
3.9
Piotroski
5/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HUMDF buys
0
O buys
0
No recent congressional trades found for HUMDF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHUMDFO
Forward yield484.14% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$47900.01M ✓$34.2K
Annual income after 10y$34,060,653,223.60 ✓$5,102.74
Total dividends collected$46687.76M ✓$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: HUMDF vs O ($10,000, DRIP)

YearHUMDF PortfolioHUMDF Income/yrO PortfolioO Income/yrGap
1← crossover$59,114$48,414.43$10,818$608.16+$48.3K → HUMDF
2$330,728$267,475.81$11,787$741.68+$318.9K → HUMDF
3$1,752,431$1,398,551.73$12,946$911.00+$1.74M → HUMDF
4$8,800,812$6,925,711.29$14,345$1,127.94+$8.79M → HUMDF
5$41,922,789$32,505,919.38$16,056$1,409.05+$41.91M → HUMDF
6$189,569,894$144,712,509.91$18,171$1,777.83+$189.55M → HUMDF
7$814,403,207$611,563,420.90$20,820$2,268.21+$814.38M → HUMDF
8$3,326,842,984$2,455,431,552.18$24,188$2,929.90+$3326.82M → HUMDF
9$12,933,979,587$9,374,257,594.32$28,533$3,837.11+$12933.95M → HUMDF
10$47,900,011,382$34,060,653,223.60$34,235$5,102.74+$47899.98M → HUMDF

HUMDF vs O: Complete Analysis 2026

HUMDF — Stock

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

Full HUMDF Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this HUMDF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HUMDF vs SCHDHUMDF vs JEPIHUMDF vs KOHUMDF vs MAINHUMDF vs STAGHUMDF vs ADCHUMDF vs NNNHUMDF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.